Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a drug manufacturer that develops and markets madicines of different types. One of its main products, Linaclotide, is a FDA-approved drug marketed since December 2012. Also, just recently in February 2014, the company was approved allowance by the United States Patent and Trademark Office (USPTO) to apply a patent on LINZESS® and will be protect through 2031.[1] The company is publicly listed on NASDAQ with the symbol "IRWD".
| Company type | Public |
|---|---|
| NASDAQ:IRWD | |
| Industry | Biofuels And Bioproducts Industry |
| Founded | 1998 |
| Headquarters | Cambridge, Massachusetts. |
| Products | Bioproducts |
| Website | www |
Research and Products
This principal product of Ironwood Pharmaceuticals was approved by the US Food and Drug Administration (FDA) in August 2012, and reached the US market in December 2012. The drug is focused on treating irritable bowel syndrome and related symptoms, which according to the National Institutes of Health (NIH) affects around 20% of Americans. Linaclotide is estimated to reach blockbuster status in around the year 2021, based on the forecast of market research firm Decision Resources. [2]
IW-9179
The company is also doing research on treatment for painful disorders of the small intestine, and has an early-stage product called IW-9179.[3] The durg has just past Phase 2a study in 2013, and showed effects in treating Functional Dyspepsia (FD).[4]
Corporate Affairs
Patent Notice
In February 2014, Ironwood Pharmaceuticals was issued allowance by the United States Patent and Trademark Office (USPTO) to apply a patent on LINZESS® and will be protect through 2031. The patented method aims at achieving stable condition of the drug at room temperature and can dissolve in stomach with capsule and suitable for oral dosing.[5] This is another step forward in research and experiments based on Linaclotide usage.
References
- ^ http://finance.yahoo.com/news/ironwood-receives-notice-allowance-methods-130000775.html
- ^ http://decisionresources.com/News-and-Events/Press-Releases/Irritable-Bowel-Syndrome-121912
- ^ http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=IRWD.O
- ^ http://clinicaltrials.gov/show/NCT01712412
- ^ http://www.4-traders.com/IRONWOOD-PHARMACEUTICALS-5933097/news/Ironwood-Pharmaceuticals-Inc--Ironwood-Receives-Notice-of-Allowance-for-Methods-of-Use-Formulatio-17971735